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Background-—Tubulointerstitial ﬁbrosis, the ﬁnal outcome of most kidney diseases, involves activation of epithelial mesenchymal
transition (EMT). Endothelin-1 (ET-1) activates EMT in cancer cells, but it is not known whether it drives EMT in the kidney. We
therefore tested the hypothesis that tubulointerstitial ﬁbrosis involves EMT driven by ET-1.
Methods and Results-—Transgenic TG[mRen2]27 (TGRen2) rats developing fulminant angiotensin II–dependent hypertension
with prominent cardiovascular and renal damage were submitted to drug treatments targeted to ET-1 and/or angiotensin II
receptor or left untreated (controls). Expressional changes of E-cadherin and a-smooth muscle actin (aSMA) were examined as
markers of renal EMT. In human kidney HK-2 proximal tubular cells expressing the ETB receptor subtype, the effects of ET-1
with or without ET-1 antagonists were also investigated. The occurrence of renal ﬁbrosis was associated with EMT in control
TGRen2 rats, as evidenced by decreased E-cadherin and increased aSMA expression. Irbesartan and the mixed ET-1 receptor
antagonist bosentan prevented these changes in a blood pressure–independent fashion (P < 0.001 for both versus controls). In
HK-2 cells ET-1 blunted E-cadherin expression, increased aSMA expression (both P < 0.01), collagen synthesis, and
metalloproteinase activity (P < 0.005, all versus untreated cells). All changes were prevented by the selective ETB receptor
antagonist BQ-788. Evidence for involvement of the Rho-kinase signaling pathway and dephosphorylation of Yes-associated
protein in EMT was also found.
Conclusions-—In angiotensin II–dependent hypertension, ET-1 acting via ETB receptors and the Rho-kinase and Yes-associated
protein induces EMT and thereby renal ﬁbrosis. ( J Am Heart Assoc.2016;5:e003888 doi:10.1161/JAHA.116.003888)
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T ubulointerstitial ﬁbrosis (TIF) is the ﬁnal outcome ofmany chronic kidney diseases and was considered to
involve angiotensin (Ang) II and endothelin (ET)-1.1,2 A key
event in TIF entails a phenotypic switch of epithelial cells to a
mesenchymal phenotype, a phenomenon commonly known as
epithelial mesenchymal transition (EMT).3 This process
implies loss of cell-to-cell junctions, collagen synthesis, and
acquisition of a migratory phenotype.
First identiﬁed during tissue and organ differentiation in
embryos, EMT was thereafter recognized as a key process in
wound healing, cancer development, and ﬁbrosis. Of note, it was
found to mediate TIF in chronic allograft dysfunction4 and
diabetic nephropathy,5,6 suggesting that it could be a general
mechanism leading to end-stage kidney disease. Moreover, rat
tubular cells exposed to high glucose levels were reported to
develop EMT via ET-1–dependent pathways.7 Hence, it is
conceivable that ET-1 could cause TIF by inducing EMT via
activation of 1 or both of its receptor subtypesA (ETA) andB (ETB).
To interrogate this hypothesis we used the TG[mRen2]27
rat (TGRen2), a transgenic rat model of fulminant Ang
II–dependent hypertension featuring early-onset severe car-
diovascular and renal damage with ET-1–dependent TIF.8–10 In
this model we examined the expressional changes of
epithelial (E-cadherin) and mesenchymal markers (aSMA
and S100A4) during development of TIF. To verify the
relevance of these ﬁndings for humans, we then investigated
the effect of ET-1 on these markers and identiﬁed the ET
receptor subtype that mediates EMT in human HK-2 proximal
tubular cells. We found that ET-1 affected additional features
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of EMT, including increased collagen synthesis, activation of
metalloproteinases (MMP), and cell migration by acting
through Rho-kinase and Yes-associated protein (YAP) signal-
ing pathways.
Methods
In Vivo Experiments
The protocol of this experiment is only brieﬂy described here
because it was previously published.10,11 Male heterozygous
[mRen2]27 rats (TGRen2) at age 5 weeks underwent mea-
surement of body weight and systolic blood pressure (BP, tail-
cuff method) and then were matched for both body weight
and BP and randomly allocated to receiving 1 of the following
treatments for 4 weeks: placebo (n = 8), mixed ETA/ETB
endothelin receptor antagonist bosentan (100 mg/kg body
weight) (n = 5), AT-1 receptor-selective antagonist irbesartan
(50 mg/kg body weight) (n = 5), ETA-selective endothelin
receptor antagonist BMS-182874 (BMS; 52 mg/kg body
weight) (n = 4), combined treatment with irbesartan
(50 mg/kg body weight), and BMS (52 mg/kg body weight)
(n = 5). The animal handling followed guidelines for animal
studies; the institutional review board approved the protocol.9
At sacriﬁce after 4 weeks, organs, including the kidneys,
were quickly removed, weighed, snap frozen in isopentane
precooled on dry ice, and were kept stored in liquid nitrogen
until analyzed.
Immunohistochemistry, histomorphometry, and double
immunoﬂuorescence were performed on the kidney sections
used for our previous studies.9
Immunohistochemistry
Serial sections were incubated in blocking serum solution at
room temperature (RT) for 60 minutes in a humidiﬁed
chamber. After endogenous peroxidase was blocked with
1.5% hydrogen peroxide, the sections were incubated with the
primary antibody against E-cadherin (dilution 1:300) or aSMA
(both rabbit polyclonal from Abcam, Cambridge, UK; ab15734,
dilution 1:50), or S100A4 (rabbit polyclonal, Santa Cruz,
Dallas, TX; dilution 1:100) at +4°C. The immunoreaction was
stopped with PBS and visualized by incubating the sections
with the secondary antibody (anti–rabbit polyclonal HRP,
Chemicon, Billerica, MA) labeled with horseradish peroxidase
and 3,30-diaminobenzidine (DAB, Sigma-Aldrich, St. Louis,
MO). The sections were counterstained with hematoxylin,
dehydrated, cleared, and mounted.
Histomorphometry
This analysis was performed by a single examiner who was
kept blind to treatment, using a Leica DM photomicroscope
equipped with QWin Standard Image Analysis software (Leica
Microsystems GmbH, Wetzlar, Germany). Routines were
speciﬁcally created to estimate immunoreactivity for E-
cadherin, aSMA, or S100A4 in an operator-independent
fashion. The entire cortical region was examined at magniﬁ-
cation of 920 in 6 sections for each rat, with about 300 views
for each treatment. Vessels and glomeruli were excluded from
the analysis. Immunoreactivity was quantiﬁed in each ﬁeld as
the percentage of total surface area. All sections were stained
during the same experiment to minimize experimental
variability and examined by a single operator blinded to
treatments. The intra-assay and interassay coefﬁcients of
variation were less than 5% and 10%, respectively.
Double Immunoﬂuorescence
Serial sections 4 lm thick of frozen kidneys were ﬁxed with
4% paraformaldheide for 8 minutes at +4°C. After rinsing in
PBS and incubation with BSS for 60 minutes at RT, the
sections were sequentially incubated with primary antibodies
to detect E-cadherin (Abcam, Cambridge, UK: green) and
aSMA (Abcam, Cambridge, UK: red), or E-cadherin (green) and
S100A4 (red), or laminin (green) and aSMA (red) and then
with the secondary antibodies conjugated with Alexa Fluor
488 and Alexa Fluor 594 for 24 hours. Subsequent exposure
to DAPI allowed detection of the nuclei. The omission of the
primary antibody conﬁrmed the speciﬁcity of the immunore-
action. The analysis was performed by a single examiner blind
to treatment, using QWin Standard Image Analysis software
(Leica Microsystems GmbH, Wetzlar, Germany).
In Vitro Experiments
Cell Culture
The human kidney cell line HK-2 (American Type Cell Culture,
ATCC, Manassas, VA), which was originally derived from the
proximal tubules of a healthy human subject,12 was used as a
model of differentiated proximal tubule cells. Proximal tubular
cells are known to express mostly the ETB receptor subtype.
13
The cells were cultured in Dulbecco’s Modiﬁed Eagle’s
Medium/Nutrient Mixture F-12 Ham (DMEM-F12; Sigma-
Aldrich, St. Louis, MO) medium added with 1% glutamine
(Sigma Aldrich, St. Louis, MO), 1% antibiotic/antifungin
(Sigma Aldrich, St. Louis, MO), 10% fetal bovine serum (FBS)
(Sigma Aldrich, St. Louis, MO) and kept at 37°C and 5% CO2.
HK-2 showed a polygonal and cobblestone appearance and
expressed E-cadherin, ZO-1, a-actin, cytokeratin, and a3-b1
integrin (expression assessed with both RT-PCR and immuno-
histochemistry), which are markers of the epithelial pheno-
type. HK-2 cells maintained this epithelial phenotype for
10 days, after which there was a gradual transition from the
polygonal to a spindle morphology.
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To ascertain if ET-1 triggers EMT and identify the time at
which EMT is appreciable in HK-2, the cells were seeded at
density 2 9 105 cellule/well in 6-well (9.62 cm2/well) plates
and, after reaching subconﬂuence, were starved with medium
added with 1% FBS and then stimulated with 107 mol/L ET-
1. Stimulation with 2 nmol/L TGFb was used as a positive
control. ET-1 and TGFb were added every 24 and 48 hours,
respectively.6,14 After 12, 24, 48, 72, and 96 hours and 7 and
10 days of treatment, cells were lysed, and RNA and/or
proteins were extracted following standard protocols.
EMT is a multistep process that entails blunting of the
epithelial marker expression along with appearance of the
mesenchymal markers leading to coexpression of both
markers, increase of metalloproteinases, and acquisition of
cell migration properties. Hence, to investigate if ET-1 induces
EMT in humans, we exposed the HK-2 cells to ET-1
(107 mol/L) and examined the expressional changes of (1)
E-cadherin and aSMA genes, (2) E-cadherin, aSMA, and
vimentin proteins, (3) both of these epithelial and mesenchy-
mal markers simultaneously, (4) metalloproteinases MMP-2
and MMP-9, (5) cell migration, and (6) the increase of markers
of ﬁbrosis such as collagens COL1A, COL2A, COL3A, and
COL4A. ETB-selective (BQ-788, ETA/ETB Ki ratio >1 9 10
4)
and mixed ETA/ETB (macitentan, ETA/ETB Ki ratio 6 9 10
3)
antagonists were used to ascertain the ET-1 receptor subtype
(s) mediating EMT in HK-2 cells exposed to ET-1. Cells were
treated with the antagonist (105 mol/L) for 1 hour before
being exposed to 107 mol/L ET-1.
Gene Expression
To assess the effects of ET-1 in HK-2 cells, the expression of E-
cadherin, aSMA, MMP-2, MMP-9, COL1A, COL2A, COL3A, and
COL4A mRNA was examined using real-time PCR with Universal
Probe Library Probes (Roche, Basel, Switzerland) in the Light
Cycler 480 Instrument (Roche, Basel, Switzerland). After treat-
ment gene expression was calculated by the comparative Ct
(2ΔΔCt) method: each sample was quantiﬁed against its
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcript
content and normalized to the control group.15 The sequences of
primers used in real-time PCR are reported in Table.
Protein Expression
After 7 and 10 days of stimulation with ET-1 or TGFb, proteins
extracted fromHK-2 cells with tissue protein extraction reagent
(T-PER , Thermo Scientiﬁc, #78510, Rockford, IL) were exposed
to a protease inhibitor (Roche, Basel, Switzerland). The
concentration was then measured using the BCA quantiﬁcation
assay (Pierce, Thermo Scientiﬁc, #23225, Rockford, IL). Equal
amounts of proteins (50 lg) were denatured in boiling water
for 5 minutes, separated by 10% SDS-PAGE gel, and
electrophoretically transferred onto nitrocellulose membranes
(GE Healthcare, RPN203D, Buckinghamshire, UK). The mem-
branes were blocked for 3 hours with 5% skim milk (Carl Roth,
T145.2, Karlsruhe, Germany) in PBS added with 0.1% Tween
followed by overnight incubation at 4°C or 1 hour at room
temperature with the following antibodies: polyclonal antibody
against E-cadherin (sc-7870, Santa Cruz, Dallas, TX), mono-
clonal antibody against aSMA (kind gift from Prof. Giulio
Gabbiani, University of Geneva, Geneva, Switzerland), mono-
clonal antibody against vimentin (clone V9, 18-0052, San
Giuliano Milanese, Italy), and monoclonal antibody against
MMP9 (sc-10737, Santa Cruz, Dallas, TX). A monoclonal
antibody against GAPDH (Cell Signaling, 14C10, Danvers, MA)
was used for normalization. Membranes were incubated with
horseradish peroxidase (HRP)-linked antimouse (1:2000) or
antirabbit (1:2000) secondary antibodies (Dako, P0260 and
P0448, Glostrup, Denmark). Proteins were visualized with a
luminol-based chemiluminescent substrate (Pierce, Thermo
Scientiﬁc, 32106, Rockford, IL). Images were processed and
analyzed with molecular imager VersaDoc system (Biorad,
Hercules, CA).
Immunoﬂuorescence
After HK-2 cells were grown to a density of 29 104 cells/slide
with or without 107 mol/L ET-1 for 7 days, they were ﬁxed
with 1% paraformaldehyde for 20 minutes and permeabilized
Table. Primer Sequences of the Genes Used for Real-Time
PCR
Gene Primers
E-cadherin (epithelial)
(CDH1)NM_004360.3
cggggtctccctgtgttactactctgggaggccaagatg
Actin, alpha 2, smooth
muscle (ACTA2)
NM_001613.2
ctgttccagccatccttcattcatgatgctgttgtaggtggt
Collagen, type I,
alpha 1 (COL1A1)
NM_000088.3
gggattccctggacctaaagggaacacctcgctctcca
Collagen, type II,
alpha 1 (COL2A1)
NM_001844.4
cctgtaagaccttcgggtcaactcagggggcatttgact
Collagen, type III,
alpha 1 (COL3A1)
NM_000090.3
ctggaccccagggtcttcgaccatctgatccagggtttc
Collagen, type IV,
alpha 1 (COL4A1)
NM_001845.4
ctcaaaggtttgccaggtctaacgcctggtaccccaat
Matrix metallopeptidase
2 (MMP2)
NM_001127891.2
gcttctgccctgaccaagaggtgtaaatgggtgccatc
Matrix metallopeptidase
9 (MMP9)
NM_004994.2
gaaccaatctcaccgacagggccacccgagtgtaaccata
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with methanol for 5 minutes at 20°C. To investigate if HK-2
cells coexpress epithelial and mesenchymal markers, after
washing with PBS, the cells were incubated for 2 hours at 32°C
with a monoclonal antibody against aSMA (kind gift from Prof
Giulio Gabbiani), and then bound antibodies were detected by
using Alexa Fluor 594-conjugated goat anti–mouse IgG
secondary Ab (1:500; Invitrogen, San Giuliano Milanese, Italy)
for 1 hour at room temperature. The samples were after-
incubated with a monoclonal antibody against ZO-1 (Invitrogen,
San GiulianoMilanese, Italy) for 2 hours at 32°C andwith Verde
DL 488 JACK (1:400; Jackson ImmunoResearch, West Grove,
PA) for an additional 1 hour. The samples were analyzed with
Leica TCS SP5 confocal microscopy by using laser excitation at
488 nm and LAS AF software.
To investigate if MMP9 synthesis is triggered by ET-1 in
HK-2 cells, the cells were incubated for 2 hours at 32°C with
a monoclonal antibody against MMP9 (sc-10737, Santa Cruz,
Dallas, TX). The immunoreaction was detected by using Alexa
Fluor 594-conjugated goat anti-mouse IgG secondary Ab
(1:500; Invitrogen, San Giuliano Milanese, Italy) for 1 hour at
room temperature. The nuclei were counterstained with DAPI
(Sigma-Aldrich, St. Louis, MO), and the sections were
analyzed with Leica DM microscopy.
Gelatin Zymography
HK-2 cells were exposed to ET-1 for 7 days, and then the
conditioned medium was collected after 24 hours. Hence, HK-
2 cells were examined for MMP9 activity after 8 days of
exposure to ET-1. After centrifuging of the medium at 800g for
5 minutes, the supernatant was 30-fold concentrated in
Amicon Ultra-0.5 centrifugal ﬁlter devices with a nominal
molecular weight limit of 3K (Merck Millipore Ltd, Tullagreen,
Carrigtwohill Co Cork, Ireland). Twenty microliters of concen-
trated supernatant was added with 49 nonreducing sample
buffer (1.25 mol/L Tris-HCl pH 6.8, 10% [w/v] sodium
dodecyl sulfate [SDS], 40% [v/v] glycerol, 1% bromophenol
blue) (3:1, v/v) and electrophoresed on 8% SDS-PAGE
containing 1% gelatin (Sigma-Aldrich, St. Louis, MO) as
MMP-9 substrate. The gels were then washed twice with
2.5% Triton X-100 and incubated overnight at 37°C in
developing buffer (50 mmol/L Tris-based, 200 mmol/L NaCl,
10 mmol/L CaCl2, pH 7.4). The gels were stained with 0.5%
(w/v) Coomassie Brilliant Blue R-250 (Sigma-Aldrich, St.
Louis, MO) in 30% methanol and 10% acetic acid and
subsequently destained in a 30% methanol and 10% acetic
acid solution. Gelatinases appear as clear bands against blue
background. Recombinant protein molecular weight markers
were used to estimate the weights of the gelatinolytic bands,
and conditioned medium from A549 cells treated with TNFa
10 ng/mL was used as positive control. Relative enzyme
amounts were quantiﬁed by measuring the intensity of the
bands with the pixel-based densitometer program Quantity
One 1-D Analysis Software (Bio-Rad Laboratories, Inc,
Hercules, CA). Intensity values of MMP9 obtained for each
experimental sample were reported over the untreated cells.
Real-Time Migration Assays
Cell migration was assessed with the xCELLigence Real-Time
Cell Analyzer (RTCA) DP system (Roche Diagnostics, Man-
nheim, Germany), a cell–electrode impedance detection-
based technology. The system relies on microelectronic
biosensors covering the bottom of each well in the E-plates
(Roche Diagnostics, Mannheim, Germany) that measure the
electrical impedance of the cell population inside each well.
The impedance is recorded as a cell index, a dimensionless
parameter that reﬂects cell viability and adhesion.
The migration assay was performed using CIM-Plates 16
(Roche Diagnostics, Mannheim, Germany), characterized by
wells equipped with an upper and a lower chamber separated
by a microporous membrane with randomly distributed
8 lmol/L pores. HK-2 cells were plated after 7 days of
exposure to ET-1 on the underside of the upper wells, and the
signal was recorded every 5 minutes for the ﬁrst 8 hours and
then every 15 minutes for the next 15 hours. Each cell index
value was then ratioed to the cell index recorded at the
baseline for the same well, making the normalized cell index
values comparable between wells and plates. Analysis was
performed with RTCA software (version 1.2, Roche Diagnos-
tics, Mannheim, Germany).
MYPT and YAP Phosphorylation
After HK-2 cells had been stimulated with ET-1 for 5 minutes,
30 minutes, or 1 hour, proteins were extracted, and
immunoblotting was performed following previously reported
protocols with minor modiﬁcations.16 After the proteins were
Figure 1. Blood pressure in TGRen2 rats. Systolic blood pres-
sure values in the TGRen2 rats at baseline (age 5 weeks) and
after 4 weeks of placebo (controls; n = 8), or treatment with
irbesartan (n = 5), bosentan (n = 5), BMS-182874 (n = 4), and
irbesartan plus BMS-182874 (n = 5). At age 9 weeks control rats
showed signiﬁcantly increased blood pressure. The pressor
increase was prevented only in the irbesartan group.
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transferred onto the membranes, they were blocked for
2 hours with nonfat dry milk (5% in TPBS) and subsequently
incubated overnight with a primary polyclonal antibody
antiphospho-MYPT-1 (Thr853) (1:1000; Cell Signaling, Dan-
vers, MA) and anti-MYPT-1 (1:1000; Cell Signaling, Danvers,
MA). GAPDH was used as loading control and detected after
the membranes had been incubated overnight with mono-
clonal antibody against GAPDH (1:5000; Millipore, Temecula,
CA). After incubation with proper secondary antibodies, HRP-
conjugated immunoreactive proteins (Amersham Biosciences,
Uppsala, Sweden) were visualized by chemiluminescence
using Super Signal West Pico Chemiluminescent Substrate
(Pierce, Rockford, IL). Protein expression was quantiﬁed using
densitometric semiquantitative analysis and NIH image soft-
ware. For YAP and phospho-YAP detection, immunoblot and
image analysis were performed as previously described for E-
cadherin staining. Monoclonal antibody against YAP (1:1000;
sc-101199, Santa Cruz, Dallas, TX) and polyclonal antibody
against Phospho-YAP (Ser 127; 1:1000; Cell Signaling, #4911,
Danvers, MA) (both YAP and phospho-YAP kind gifts from
Prof. Stefano Piccolo, University of Padova, Italy) were used.
To assess intracellular localization of YAP, 100 randomly
f g h i j
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Figure 2. Markers of EMT in kidney of TGRen2 rats. A, Immunostaining for E-cadherin (top panels), aSMA (middle panels), and S100A4
(bottom panels) of TGRen2 kidney sections after placebo treatment (a, f, k), irbesartan (b, g, l), bosentan (c, h, m), BMS 182874 (BMS) (d, i, n),
and irbesartan on top of BMS (e, j, o). The speciﬁc signal pertaining to E-cadherin is barely evident (empty arrows) in most tubules of placebo
(a) and BMS-treated (d) groups, where it is evident only in the vessel wall (asterisks). E-cadherin can be clearly appreciated (full arrows) in the
irbesartan- (b) and bosentan-treated (c) groups. aSMA immunosignal is well recognizable in the proximal tubules of placebo (f) and BMS (i)
groups but not in irbesartan- (g), bosentan- (h), and irbesartan+BMS- (j) treated groups. Note that tubules are enlarged in large part of the
sections of placebo TGRen2 kidneys (f). The immunoreaction for S100A4 was evident in the tubules of placebo (k) and BMS (n) groups, but not
in irbesartan- (l) and bosentan-treated (m) groups. As expected, the immunosignal was clearly appreciated in the glomeruli. Inset, The omission
of the primary antibody conﬁrmed the speciﬁcity of the reaction. B, Quantitative analysis of immunostaining for the epithelial marker E-
cadherin and the mesenchymal markers aSMA and S100A4 in the kidney of TGRen2 rats after exposure to in vivo treatment with irbesartan,
bosentan, BMS, and irbesartan on top of BMS. E-cadherin (left panel) increased, while aSMA (middle panel) and S100A4 (right panel)
decreased, after irbesartan and bosentan treatment, as compared to placebo. Irbesartan on top of BMS, but not BMS alone, prevented aSMA
and S100A4 increases. Speciﬁc immunoreactivity was estimated as the percentage of total surface area. Only signiﬁcant comparisons were
reported. The number of animals is shown in Figure 1.
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chosen cells per treatment were analyzed. Cells displaying
preferential localization of YAP in the nucleus, cytoplasm, or in
both nucleus and cytoplasm were counted for each treat-
ment.17
Power Calculation and Statistical Analysis
Sample size was preliminarily calculated by nQuery Advisor
software (version 7.0; Statistical Solutions, Saugus, MA).
When applied to E-cadherin, S100A4, and aSMA immunosig-
nals, a sample size of 200 views from 5 rats for each
treatment group was estimated to provide 99% power to
detect a difference between means of 0.34, assuming a
common SD of 0.8 for both immunosignals and a type 1 error
of 5%. Results are expressed as mean  SEM. The number of
independent experiments is reported in the Results and the
legends to the ﬁgures.
T-test and 1-way analysis of variance (ANOVA) with Bonfer-
roni post-hoc correction for multiple comparisons, or Mann–
Whitney and Kruskall-Wallis tests for the variables that showed
a skewed distribution, were used to evaluate differences
between or across groups, as appropriate. To allow for
comparison across markers, the changes of protein expression
induced by ET-1, alone or with antagonists, were expressed as
percentage variation from the baseline values (control cells) set
at 0. Chi-square test followed by post-hoc comparison proce-
dure that eliminates type 1 error was used to evaluate
differences of percentage localization of YAP between groups
(https://www.youtube.com/watch?v=Rp0qorrPXA0#t=399.
41984921). The statistical signiﬁcance of these changes was
evaluated by a 1-sample t-test versus the null hypothesis of no
change. P < 0.05 was considered statistically signiﬁcant.
Analyses were performed with SPSS (version 23.0 for Mac, IBM
Corp., Armonk, NY).
Study Approval
The animal handling followed guidelines for animal studies, and
the protocol was approved by the institutional review board.9
Results
Regulation of EMT by the Renin-Angiotensin (RAS)
and ET-1 Systems in a Blood Pressure-
Independent Fashion
Systolic blood pressure (SBP) increased signiﬁcantly during
the study period in TGRen2 placebo-treated (controls; n = 8)
rats (Figure 1); the Ang II type 1 receptor (AT1) antagonist
irbesartan (n = 5) abolished this increase, whereas bosentan
(n = 5) and BMS 182874 (BMS) (n = 4), nonselective (ETA/
ETB) and ETA-selective receptor antagonists, respectively,
were not effective (Figure 1).10
Placebo-treated TGRen2 rats showed weaker E-cadherin
immunostaining in the tubules (Figure 2A) than irbesartan- or
bosentan-treated rats, as evidenced at a quantitative analysis
(Figure 2B). They also showed enlarged proximal tubules with
B
Figure 2. Continued.
DOI: 10.1161/JAHA.116.003888 Journal of the American Heart Association 6
Endothelin-1 in Renal EMT Seccia et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 at UNIV STUDI PADOVA on July 22, 2016http://jaha.ahajournals.org/Downloaded from 
evident aSMA immunostaining (Figure 2A-f) that was only
barely detectable in a control group of normal Sprague-
Dawley rats (immunostained percentage area 0.12  0.28).
The increased aSMA staining was prevented by irbesartan
(68%, Figure 2B), bosentan (61%, Figure 2B), and irbesar-
tan on top of BMS treatment (70%, Figure 2B) but not by
BMS alone (Figure 2B).
The placebo group also showed a scattered S100A4
immunostaining (Figure 2A-m). This was blunted by irbesartan
(39%) and bosentan (37%) (Figure 2A-n, A-o,B) and by
irbesartan and BMS (59%, Figure 2A-q,B) but not by BMS
alone (Figure 2A-p). Hence, blockade of AT1 and of ETA/ETB,
but not of ETA receptor alone, prevented EMT in the renal
interstitium and the development of TIF in TGRen2 rats, which
involves both the RAS and the ET-1 system acting via AT1 and
ETB receptors, respectively.
To ascertain the concurrence of loss of epithelial markers
alongside expression of mesenchymal markers in the same
A B
F
C D E
G H I J
K L M N O
Figure 3. Coexpression of the epithelial and mesenchymal markers in the kidney of TGRen2 rats. Double immunoﬂuorescence for E-cadherin
(green) and aSMA (red), or E-cadherin (green) and S100A4 (red) in placebo TGRen2 kidney sections that include proximal tubules. Double
immunoﬂuorescence indicates coexpression of the epithelial and mesenchymal markers, thereby suggesting EMT. Tubules showed coexpression
of aSMA and E-cadherin (A and B; yellow, arrows) in few cells, thereby suggesting, as expected, that EMT occurred in only a small number of
cells. However, some tubules showed only signal for aSMA, suggesting replacement of epithelial cells with myoﬁbroblastoid cells throughout the
tubule circumference, indicating overt ﬁbrosis (C). Coexpression of S100A4 with E-cadherin was rarely detected (D and E; arrows). The
speciﬁcity of the immunoreaction for each marker was conﬁrmed by the lack of signal after omission of primary antibody (inset). Coexpression
of E cadherin and aSMA (F–J), or E cadherin and S100A4 (K–O) was restricted to vessels (asterisk) in irbesartan- and bosentan-treated rats
(G, L, M), thereby suggesting that EMT in the nephrons was fully prevented by either AT1 antagonism or nonselective ETA/ETB antagonism. In
contrast, coexpression of epithelial and mesenchymal markers (yellow) was evident in some epithelial tubular cells after BMS (I; arrow), thereby
suggesting that ETA antagonism failed to prevent EMT. Irbesartan on top of BMS prevented coexpression of epithelial and mesenchymal
markers, indicating the beneﬁcial effect of AT1 antagonism. Yellow or orange-reddish staining indicates double labeling. 920 magniﬁcation.
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tubular cells, we immunolabeled serial sections of TGRen2
kidneys for E-cadherin andaSMAor for E-cadherin and S100A4.
Only occasionally did we ﬁnd coexpression of E-cadherin and
S100A4 in the placebo group (Figure 3D,E), whereas many
tubules showed aSMA and E-cadherin coexpression, which
sometimes involved most of the tubule circumference (Fig-
ure 3A,B). Of note, a few tubules showed exclusive aSMA
expression, indicating full transformation into mesenchymal
cells (Figure 3C). Coexpression of E-cadherin and aSMA
occurred in tubular cells of BMS-treated rats (Figure 3I) but
never in the other treatment groups (Figure 3G,H,L).
Hence, IHC and double immunoﬂuorescence also support
the contention that EMT develops in the tubules of TGRen2
rats and involves the ET-1 system acting predominantly via
ETB receptors.
Expression of the Epithelial and Mesenchymal
Markers in HK-2 Cells
We exposed in vitro renal proximal tubular HK-2 cells to ET-1
to investigate if ET-1 alone could drive EMT in humans. The
peptide decreased E-cadherin gene expression at 12 hours,
with a nadir at 48 hours, an effect that persisted up to
72 hours (Figure 4) (4 independent experiments, each done
at least in duplicate). ET-1 also activated aSMA expression
(Figure 4) while leaving vimentin unaffected (data not shown).
The well-known inducer of EMT TGFb, used as positive
control, blunted E-cadherin and increased aSMA protein
expression (Figure 5A,B). Likewise, ET-1 decreased E-cadherin
(Figure 5A) and increased vimentin (Figure 5C) and aSMA
protein (Figure 5B) (time 0: n = 5; 7 days: n = 6; 10 days: n =
5; n independent experiments, each at least in duplicate).
The discontinuation of the ZO-1 signal at the membrane
level, indicating loss of tight junctions in HK-2 cells exposed to
ET-1 (Figure 6A), alongside the shift toward an elongated cell
shape and appearance of aSMA altogether also indicated that
ET-1 drives EMT.
Pretreatment of HK-2 cells with BQ-788, or macitentan,
prevented the ET-1-induced decrease of E-cadherin at day 10
(Figure 5D) (3 independent experiments, each done at least in
duplicate); both antagonists also appeared to blunt the ET-1–
induced increase in aSMA protein expression, although the
effectofBQ-788didnotattainstatisticalsigniﬁcance(Figure 5E)
(3 independent experiments, each done at least in duplicate).
Likewise,bothantagonistspreventedtheET-1–inducedincrease
of vimentin at day 7 (Figure 5F) (3 independent experiments,
eachdoneat least induplicate).Moreover,macitentanprevented
aSMA appearance in ET-1–treated cells (Figure 6B).
Along with the fact that the ETB was found to be on
average 4.5-fold more abundant than ETA (Figure 6C), these
observations collectively suggest that in human renal proximal
tubular cells ETB is the major receptor subtype mediating ET-
1–induced EMT.
ET-1 Promotes Collagen Synthesis, MMP9
Activity, and Cell Migration in HK-2 Cells
We evaluated collagen and MMP synthesis and the migration
properties of ET-1–treated HK-2 cells to determine if ET-1 is
Figure 4. Time course of gene expression of E-
cadherin and aSMA in HK-2 cells after exposure to
ET-1. A, E-cadherin gradually decreased until it
reached a nadir at 48 to 72 hours after the ET-1
challenge, and it returned to pretreatment levels
after 96 hours. B, aSMA increased at 24 hours and
at 96 hours, but its changes followed a less
consistent course. It was back to pretreatment
levels by day 10. Values are means of 4 indepen-
dent experiments, each done at least in duplicate. P
< 0.05, ANOVA with Bonferroni post-hoc test for
multiple comparisons.
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sufﬁcient for full transition of epithelial into mesenchymal cells.
We found that after 7 days of exposure ET-1 increased collagen
(COL)1A (+87%), COL3A (+114%), and COL4A (+56%) genes
(Figure 6D) (4 independent experiments, each in duplicate).
The expression of MMP2 gene (Figure 7A) (4 independent
experiments, each in duplicate) and MMP9 protein (Figure 7B,
C) was increased by ET-1; macitentan prevented the MMP9
increase (Figure 7B,C) (3 independent experiments, each in
duplicate).
We found that ET-1 treatment increased MMP9 activity
(Figure 7D), but less than TGFb; this increase was prevented
by both macitentan and BQ-788 (Figure 7D) (3 independent
experiments, each in duplicate). By contrast, MMP2 activity
did not signiﬁcantly change at any time (data not shown),
indicating that activation of ETB subtype receptor regulates
MMP9 but not MMP2 activity in HK-2 cells.
After 7 days of treatment with ET-1, HK-2 cells acquired a
proliferating/migratory phenotype, as shown by the increase in
the cell index (P < 0.001 versus unstimulated; Figure 7E,F; 3
independent experiments, each in duplicate). Both macitentan
and BQ-788 prevented cell migration, thus indicating that this
phenomenon occurs via ETB receptor subtype (Figure 7E,F).
Because the Rho-kinase pathway is activated in EMT,18,19
and ET-1 acts via Rho-kinase and YAP signaling pathways,20
we measured Rho-associated serine-threonine protein kinase-
1 (Rock-1) expression and MYPT-1 phosphorylation, an index
of ROCK activity, in HK-2 cells exposed to ET-1. We found that
ET-1 induced phosphorylation of MYPT-1, an effect that was
prevented by macitentan (Figure 8A) and BQ788 (Figure 8B)
(3 independent experiments, each in duplicate) but left Rock-1
unaffected (data not shown). Because activation of the YAP
has been recently described in EMT,21 and a link between E-
cadherin and YAP has been suggested,22–24 we also examined
YAP activity in HK-2 cells after an ET-1 challenge. We found
that 30 minutes of ET-1 exposure doubled the ratio of YAP to
phosphorylated YAP (Figure 9A) (3 independent experiments,
A B C
D E F
Figure 5. Time course of the changes of E-cadherin (A), aSMA (B), and vimentin (C) protein expression in
HK-2 cells exposed to ET-1 or TGFb. Both 107 mol/L ET-1 and 2 nmol/L TGFb, a well-known inducer of
EMT used as a positive control, caused a progressive decrease of E-cadherin and an increase of aSMA and
vimentin protein expression. Values are expressed as fold changes of the values recorded in untreated cells
at time 0, set to 1 (0: n = 5; 7 days: n = 6; 10 days: n = 5, n: independent experiments, each at least in
duplicate). Percentage changes of protein expression of E-cadherin (D), aSMA (E), and vimentin (F) over
control untreated cells, set to 0, after exposure of HK-2 cells to ET-1 for 10 days, or to macitentan and the
selective ETB receptor antagonist BQ-788 on top of ET-1. Asterisks indicate comparisons between ET-1 and
control untreated cells (*P < 0.05; **P < 0.01). Values are means of 3 independent experiments, each done
at least in duplicate.
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each in duplicate). This ﬁnding was consistent with a high YAP
immunoﬂuorescent signal in the nucleus after exposure of HK-
2 cells to ET-1 (Figure 9B,C versus untreated control cells),
indicating that ET-1 hindered phosphorylation and transloca-
tion of YAP to the nucleus, where YAP activates transcription
by binding to DNA. Pretreatment of HK-2 cells with either
macitentan or BQ-788 prevented the ET-1–induced increase
of YAP immunoﬂuorescent signal in the nucleus (Figure 9B,C)
(3 independent experiments, each in duplicate). Hence, ET-1
drives EMT via Rho-kinase and YAP signaling pathways.
A B
C
D
Figure 6. Disruption of cell junctions (panel A), onset of aSMA (panel B), expression of ET receptor
subtypes (panel C), and changes of collagens after exposure of HK-2 cells to ET-1 (panel D). A, Confocal
analysis of HK-2 cells, which revealed integrity of the tight junctions immunolabeled in green with antibody
against ZO-1. After treatment with ET-1, the junctions appeared to be partially disrupted, and aSMA (red) was
evident in some cells. B, Onset of aSMA (red) was prevented by macitentan pretreatment. ZO-1 and the nuclei
are labeled in green and blue, respectively. C, ETB was expressed more markedly than ETA in HK-2 cells, with a
ratio ETA/ETB equal to 4.5. The omission of primary antibody conﬁrmed the speciﬁcity of the reaction (inset).
D, Gene expression of collagen 1a (COL1A), 2a (COL2A), 3a (COL3A), and 4a (COL4A) in HK-2 cells at 24
hours, 48 hours, and 7 days after exposure to ET-1 (4 independent experiments, each in duplicate). The value
measured at time 0 for each gene set at 1 was used as control. *P = 0.05; ***P = 0.005, vs time 0.
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Discussion
We showed that the development of TIF is accompanied by
EMT in TGRen-2 rats. The latter was evidenced by reduced
expression of the epithelial marker E-cadherin and
augmented expression of 2 mesenchymal markers, aSMA
and S100A4. The coexpression of epithelial and mesenchy-
mal markers in the same cells, which did not occur in
Sprague-Dawley rats, unambiguously proved the occurrence
of EMT. Moreover, this study showed that ET-1 induces EMT,
A B
C D
Figure 7. Gene expression of metalloproteinases (MMP) (panel A), immunoﬂuorescence of MMP9 (panel
B), protein expression of MMP9 (panel C), and cell migration after exposure of HK-2 cells to ET-1 (panel D).
A, MMP-2 transiently increased after 12 hours of exposure to ET-1 (4 independent experiments, each in
duplicate). No signiﬁcant differences between times were found for MMP-9 gene expression. B, MMP9 (red)
in HK-2 cells after incubation was evident after treatment with ET-1 (top) and blunted after pretreatment
with macitentan (bottom). The omission of primary antibody conﬁrmed the speciﬁcity of the reaction (inset).
C, MMP9 increased after treatment with ET-1 for 7 days, and macitentan was effective in preventing its
expression (3 independent experiments, each in duplicate). D, Because gene and/or protein expression
cannot parallel enzymatic activity of MMP, we measured MMP9 protein activity in HK-2 cells exposed to ET-
1 or macitentan or BQ-788 on top of ET-1 for 24 hours. Untreated cells were used for comparison (3
independent experiments, each in duplicate). TGFb was used as positive control. E, Representative curves
showing cell migration, as assessed with cell–electrode impedance detection-based technology. ET-1
(turquoise) was able to induce migration, similar to that induced by the well-known EMT inducer TGFb
(green). Untreated cells (purple) were used as negative controls. ET-1–induced cell migration was abolished
by pretreatment with macitentan (red) and BQ-788 (blue). A.U., arbitrary units. F, Cell index values recorded
12 hours after the treatment. Mean values of 3 independent experiments, each in duplicate. *P = 0.01.
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and thereby TIF, by acting via ETB receptor-mediated
mechanisms. In a model of fulminant hypertension with
early-onset renal and cardiovascular damage created with
the insertion of the mouse Ren-2 gene into the rat genome,8
irbesartan lowered blood pressure, but the mixed ETA/ETB
receptor antagonist bosentan did not.11 Both drugs pre-
vented renal TIF and cardiac perivascular ﬁbrosis, whereas
the ETA-selective antagonist BMS aggravated it, so there
seems to be a dissociation between development of
hypertension and TIF.9,10 This dissociation between BP and
ﬁbrosis is consistent with data found in transgenic mice
overexpressing human ET-1 gene25 and in L-NAME–treated
rats treated with an ETA subtype-selective receptor antag-
onist.26
A B
Figure 8. Changes of phosphorylation of MYPT-1 after exposure of HK-2 cells to ET-1. A, Time course of
MYPT-1 phosphorylation showed that the ratio of phosphorylated MYPT-1 to MYPT-1 increased, as
expected, early, ie, after 5 and 30 minutes of exposure of HK-2 cells to ET-1. Macitentan effectively
prevented such an effect. B, BQ-788 also prevented the increase in the phosphorylated MYPT-1/MYPT-1
ratio induced by ET-1. Mean values of 3 independent experiments, each in duplicate.
E F
Figure 7. Continued.
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Of note, EMT changes were prevented by irbesartan and
bosentan, which effectively prevented TIF, but not by BMS.9
Thus, in the kidney the occurrence of EMT involves both Ang II
and ET-1 acting via ETB receptors but independent of blood
pressure changes.
Importantly, the role of ET-1 in EMT found in vivo was
conﬁrmed in vitro: exposure of human proximal tubular HK-2
cells to ET-1 changed the expression of E-cadherin and aSMA
in a way closely mimicking the in vivo ﬁndings and by action
via similar effectors. In TGRen-2 rats, which have an activated
ET-1 system,27 the ETA receptor antagonist BMS did not
prevent, but rather worsened, TIF9 and EMT, suggesting that
ET-1 induced EMT via ETB receptors. The latter can be
overactivated when ETA receptors are blocked. In vitro the ET-
1–induced decrease of E-cadherin and the increase of
vimentin were both prevented by BQ-788, which also blunted,
albeit not signiﬁcantly, the aSMA increase.
Of note, high glucose levels, which activated ET-1 synthe-
sis,7 were found to induce EMT in rat tubular cells. However,
the role of ETA and ETB receptors remained unknown, as the
changes of EMT markers were prevented by a high (3 9 106
mol/L) BQ-123 concentration, at which selectivity for ETA can
be lost. Our present results with the highly selective ETB
antagonist BQ-788, alongside the notion that ETB is the only
ET-1 receptor subtype in the rat proximal tubules13 and in
human HK-2 cells, that ETB is expressed to a greater extent
than ETA (Figure 6C), provide compelling evidence for a major
role of ETB in EMT.
The phenotype switch of epithelial into mesenchymal cells
involves digestion of the basal membrane by metallopro-
teinases, acquisition of migratory properties, and production
of collagen. Accordingly, our cell migration studies also point
to a major role of ETB receptor in EMT: in HK-2 cells ET-1
increased MMP9 activity and cell migration, all of which were
abolished by BQ-788. This key role of the ETB receptor
subtype in EMT and TIF could partially explain the negative
results obtained with the ETA selective antagonist avosentan
in type 2 diabetic patients with overt nephropathy in the
ASCEND trial. ETA blockade conceivably leads to increased
ETB activation, thereby potentiating ETB-mediated effects.
28
MYPT-1, a member of the RhoA/ROCK signaling pathway,
is a marker of ROCK activity, which mediates ET-1 effects.29
A B C
Figure 9. YAP activation and intracellular localization of YAP after exposure of HK-2 cells to ET-1. A, Time course of YAP activation,
expressed as the ratio of YAP to phosphorylated YAP, showed YAP activation 30 minutes after ET-1 exposure. Graph bars represent mean
values  SEM. B, Immunoﬂuorescence for YAP (green) in HK-2 cells after exposure to ET-1, in the presence or absence of either macitentan
or BQ-788. In untreated HK-2 cells the immunosignal was clearly evident in both nucleus and cytoplasm. ET-1 induced blunting of the YAP
signal in the cytoplasm and its increase in the nucleus, indicating dephosphorylation of YAP and translocation to the nucleus, where it can
trigger transcription of genes involved in EMT. Pretreatment with either macitentan or BQ-788 prevented the ET-1–induced increase of YAP
immunosignal in the nucleus. Nuclei were labeled with DAPI (blue); the omission of primary antibody conﬁrmed the speciﬁcity of the
reaction (insets). C, Intracellular YAP localization. Quantitative analysis conﬁrmed that ET-1 favors translocation of YAP to the nucleus (vs
untreated cells) and that macitentan and BQ-788 prevented such translocation. For all experiments mean values of 3 independent
experiments, each in duplicate, are reported.
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We found that ET-1 induced MYPT-1 phosphorylation, likely
via activation of ROCK, thus inhibiting its activity. This
inhibition of MYPT-1 entails a key mechanism of cardiovas-
cular-renal remodeling,30,31 as it modulates the phosphoryla-
tion state of the regulatory chain of myosin II.16
YAP is an adaptor protein that regulates cytoskeleton and
cell motility by activating the transcriptional enhancer
activator domain factors (TEADs). Phosphorylation of YAP
prevents its translocation into the nucleus and the down-
stream binding to TEADs, with ensuing suppression of such
target genes as those for vimentin and aSMA.23,24 Although it
has repeatedly been proposed,21–24 a role for activation of
YAP in EMT in the kidney remained to be demonstrated. The
fact that ET-1 hindered YAP phosphorylation in human
proximal tubular cells, which points to YAP as a mediator
of ET-1–driven EMT, is a further novel ﬁnding of this study
(Figure 10).
The results obtained in vivo in a model of fulminant high
tissue Ang II hypertension suggest that Ang II and ET-1 work
in parallel in a concerted way or that ET-1 entails a
Figure 10. ET-1 drives EMT and consequently ﬁbrosis in the kidney. The cartoon depicts the epithelial-to-mesenchymal phenotypic shift
induced by ET-1 in the renal tubules. Tubular cells are tightly linked to adjacent cells by junctions (visualized as red dashes) under physiologic
conditions. On binding of ET-1, the ETB receptor subtype triggers a cell phenotype switch by which cells start expressing mesenchymal
markers such as aSMA and vimentin and gradually lose their epithelial markers, such as E-cadherin, which is the major component of
adherent junctions. The phenotypic switch is represented in this cartoon as a change of color from bluish-violet to greenish. Hence,
coexistence of blue and greenish denotes an intermediate phenotype, whereas greenish indicates a complete transition to the mesenchymal
phenotype. The cells undergoing this switch also exhibit a loss of cell junctions alongside activation of MMP-9, which promotes degradation
of the basal membrane. These concomitant processes allow the modiﬁed cells to move toward the interstitium, where they start producing
extracellular matrix proteins, including collagen (red and blue lines) that, by accumulating in the interstitium between tubules, leads to
tubulointerstitial ﬁbrosis. The magniﬁed tubular cell illustrates in greater detail the intracellular pathways activated by ET-1. Phosphorylation
of MYPT, a member of the Rho/Rock pathway that leads to cytoskeleton contraction and cell motility, is activated, whereas YAP
phosphorylation is prevented, thereby allowing entry of YAP into the nucleus and ﬁnally leading to transcription of target genes that promote
cell migration. Dashed lines indicate yet not proven effects.
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downstream effector of Ang II. The latter is also supported by
the observation that Ang II stimulates ET-1 synthesis32 and
activates EMT and by our ﬁnding that both irbesartan and
bosentan prevented TIF and EMT. This ﬁnding can be
important for developing more rational and effective strate-
gies to prevent tubular interstitial ﬁbrosis in Ang II–dependent
hypertension.
Limitations of the Study
An issue that remained unexplored is the relationship among
mechanical stress, Ang II, and ET-1 and, in particular, whether
Ang II induces EMT by activating ET-1 synthesis in the tubular
cells. The signaling pathways, including the identiﬁcation of
the G-protein subtype triggered by the ETB receptor subtype,
also compose an interesting issue that remains to be clariﬁed
with silencing experiments.
Conclusions
A better understanding of the mechanisms by which TIF
develops and the identiﬁcation of EMT as a key underlying
process, along with the demonstration of the role of ET-1 and
related pathways, can open new avenues to the prevention of
chronic kidney disease, not only in hypertension but also in
many other renal diseases, thus representing a further step
toward a personalized medicine approach to the prevention of
end-stage renal failure. A cartoon (Figure 10) schematically
recapitulates the novel pieces of evidence concerning EMT
and TIF that have been identiﬁed in this study: (1) EMT is
implicated in TIF and is regulated by both Ang II and ET-1; (2)
EMT depends on ET-1 acting via ETB receptors and the Rho-
kinase and YAP pathways.
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